Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients

British Journal of Cancer

Volumn 107, Issue 1, 2012, Pages 37-42

  Lorusso, D ^a   Scambia, G ^a   Amadio, G ^a   Di Legge, A ^a   Pietragalla, A ^a   De Vincenzo, R ^a   Masciullo, V ^a   Di Stefano, M ^a   Mangili, G ^a   Citterio, G ^b   Mantori, M ^c   Lambiase, A ^c   Bordignon, C ^c,d  

^a CATHOLIC UNIVERSITY   (Italy)

^b San Raf faele Institute   (Italy)

^c MOLMED S P A   (Italy)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

doxorubicin; NGR hTNF; ovarian cancer; vascular targeting agent

Indexed keywords

ASPARAGINYLGLYCYLARGININE TUMOR NECROSIS FACTOR; DOXORUBICIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEADACHE; HERPES ZOSTER; HUMAN; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPONATREMIA; LEUKOPENIA; LYMPHOCYTE COUNT; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; STOMATITIS; THROMBOCYTE COUNT; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; RECOMBINANT FUSION PROTEINS; TAXOIDS; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84863007720     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.233     Document Type: Article

References (30)

1. Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, De Geest K, Mutch DG, Burger RA, Swart AM, Trimble EL, Accario-Winslow C, Roth LM (2009) Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol 27: 1419-1425
2. Calcinotto A, Grioni M, Jachetti E, Curnis F, Mondino A, Parmiani G, Corti A, Bellone M (2012) Targeting TNF-a to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy. J Immunol 188: 2687-2694
3. Cannistra SA (2004) Cancer of the ovary. N Engl J Med 35: 2519-2529
4. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An endotoxin-induced serum factor that causes necrosis of tumours. Proc Natl Acad Sci 72: 3666-3670
5. Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, Corti A (2000) Enhancement of tumour necrosis factor alpha antitumour immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 18: 1185-1190
6. Curnis F, Sacchi A, Corti A (2002) Improving chemotherapeutic drug penetration in tumours by vascular targeting and barrier alteration. J Clin Invest 110: 475-482 (Pubitemid 34919701)
7. Dondossola E, Gasparri AM, Colombo B, Sacchi A, Curnis F, Corti A (2011) Chromogranin A restricts drug penetration and limits the ability of NGRTNF to enhance chemotherapeutic efficacy. Cancer Res 71: 5881-5890
8. Ferrandina G, Ludovisi M, Lorusso D, Pignata S, Breda E, Savarese A, Del Medico P, Scaltriti L, Katsaros D, Priolo D, Scambia G (2008) Phase III Trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 26: 890-896 (Pubitemid 351398081)
9. Gregorc V, Santoro A, Bennicelli E, Punt CJA, Citterio G, Timmer-Bonte JNH, Caligaris-Cappio F, Lambiase A, Bordignon C, van Herpen CML (2009) Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours. Br J Cancer 101: 219-224
10. Gregorc V, Citterio C, Vitali G, Spreafico A, Scifo P, Borri A, Donadoni G, Rossoni G, Corti C, Caligaris-Cappio F, Del Maschio A, Esposito A, De Cobelli F, Dell'Acqua F, Troysi A, Bruzzi P, Lambiase A, Bordignon C (2010a) Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours. Eur J Cancer 46: 198-206
11. Gregorc V, Zucali PA, Santoro A, Ceresoli GL, Citterio G, De Pas TM, Zilembo N, De Vincenzo F, Simonelli M, Rossoni G, Spreafico A, Vigano MG, Fontana F, De Braud FG, Bajetta E, Caligaris-Cappio F, Bruzzi P, Lambiase A, Bordignon C (2010b) Phase II study of asparagine-glycinearginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. J Clin Oncol 28: 2604-2611
12. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90
13. Kumaran GC, Jayson GC, Clamp AR (2009) Antiangiogenic drugs in ovarian cancer. Br J Cancer 100: 1-7
14. Lejeune FJ, Lienard D, Matter M, Ruegg C (2006) Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun 6: 6-23
15. Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Lisyanskaya AS, Makhson AN, Rolski J, Gorbounova VA, Ghatage P, Bidzinski M, Shen K, Yuen-Sheung Ngan H, Vergote IB, Nam JN, Park YC, Lebedinsky CA, Poveda AM (2010) Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol 28: 3107-3114
16. Mutch DG, Orlando M, Goss T, Teneriello MG, Gordon AN, McMeekin SD, Wang Y, Scribner Jr DR, Marciniack M, Naumann RW, Secord AA (2007) Randomized phase III trial of gemcitabine compared to pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 25: 2811-2818 (Pubitemid 47123191)
17. Nakasone ES, Askautrud HA, Kees T, Park JH, Plaks V, Ewald AJ, Fein M, Rasch MG, Tan YX, Qiu J, Park J, Sinha P, Bissell MJ, Frengen E, Werb Z, Egeblad M (2012) Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 21: 488-503
18. Poveda A, Vergote I, Tjulandin S, Kong B, Roy M, Chan S, Filipczyk-Cisarz E, Hagberg H, Kaye SB, Colombo N, Lebedinsky C, Parekh T, Gómez J, Park YC, Alfaro V, Monk BJ (2011) Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol 22: 39-48
19. Rangel R, Sun Y, Guzman-Rojas L, Ozawa MG, Sun J, Giordano RJ, Van Pelt CS, Tinkey PT, Behringer RR, Sidman RL, Wadih Arap W, Pasqualini R (2007) Impaired angiogenesis in aminopeptidase N-null mice. Proc Natl Acad Sci USA 104: 4588-4593 (Pubitemid 47186269)
20. Rose PG, Tian C, Bookman MA (2010) Assessment of tumour response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: A Gynecologic Oncology Group study. Gynec Oncol 117: 324-329
21. Rustin GJ. (2003) Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 21: 187-193
22. Sacchi A, Gasparri A, Gallo-Stampino C, Toma S, Curnis F, Corti A (2006) Synergistic antitumour activity of cisplatin, paclitaxel, and gemcitabine with tumour vasculature-targeted tumour necrosis factor-alpha. Clin Cancer Res 12: 175-182 (Pubitemid 43166192)
23. Sacchi A, Gasparri A, Curnis F, Bellone M, Corti C (2004) Crucial role for interferon-gamma in the synergism between tumour vasculaturetargeted tumour necrosis factor alpha (NGR-TNF) and doxorubicin. Cancer Res 64: 7150-7155 (Pubitemid 39331030)
24. Santoro A, Pressiani T, Citterio G, Rossoni G, Donadoni G, Pozzi F, Rimassa L, Personeni N, Bozzarelli S, Rossoni G, Colombi S, De Braud FG, Caligaris-Cappio F, Lambiase A, Bordignon C (2010) Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma. Br J Cancer 103: 837-844
25. Scheurich P, Thoma B, Ucer U, Pfizenmaier K (1987) Immunoregulatory activity of recombinant human tumour necrosis factor (TNF)-a: Induction of TNF receptors on human T cells and TNF-mediated enhancement of T cell responses. J Immunol 138: 1786-1790 (Pubitemid 17040802)
26. Ten Hagen TML, Van der Veen AH, Nooijen PTGA, Van Tiel S, Seynhaeve ALB, Eggermont AMM (2000) Low-dose tumour necrosis factor-a augments antitumour activity of stealth liposomal doxorubicin in soft tissue sarcoma-bearing rats. Int J Cancer 87: 829-837 (Pubitemid 30660563)
27. Van Heeckeren WJ, Bhakta S, Ortis J (2006) Promise of new vasculardisrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists? J Clin Oncol 24: 1485-1488 (Pubitemid 46638767)
28. Van Hensbergen Y, Broxtermann HJ, Rana S, van Diest PJ, Duyndam MCA, Hoekman K, Pinedo HM, Boven E (2004) Reduced growth, increased vascular area, and reduced response to cisplatin in CD13-overexpressing human ovarian cancer xenografts. Clin Cancer Res 10: 1180-1191 (Pubitemid 38198920)
29. Van Laarhoven HWM, Fiedler W, Desar IME, van Asten JJA, Sandrine Marreaud S, Lacombe D, Govaerts AS, Bogaerts J, Lasch P, Timmer-Bonte JNH, Lambiase A, Bordignon C, Punt CJA, Heerschap A, van Herpen CML (2010) Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041). Clin Cancer Res 16: 1315-1323
30. Zhang L, Conejo-Garcia JR, Katsaros D, Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G (2003) Intratumoural T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348: 203-213 (Pubitemid 36077915)